by QFR Solutions | Dec 3, 2018 | News
Source: Sienna Biopharmaceuticals WESTLAKE VILLAGE, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) — Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced top-line results from a Phase 2b study of...
by QFR Solutions | Oct 31, 2018 | News
Source: FierceBiotech 98point6, a digital health company that makes primary care doctors available to patients over cellphone messages, raised $50 million in a new financing round led by Goldman Sachs. Its platform uses artificial intelligence to automate the tasks...
by QFR Solutions | Oct 16, 2018 | News
Source: FiercePharma As the FDA gets set to decide whether Sanofi and Regeneron’s atopic dermatitis drug, Dupixent, can make a bid for asthma sales, the companies are churning out data in a variety of other conditions in hopes of boosting the product even more. The...
by QFR Solutions | Sep 26, 2018 | News
Source: FierceBiotech Alexion’s rebuilding plan has continued with another bolt-on acquisition, this time a $400 million upfront deal for rare disease specialist Syntimmune. The takeover gives Alexion control of SYNT001—a neonatal Fc receptor (FcRn) inhibitor in phase...
by QFR Solutions | Sep 17, 2018 | News
Source: FierceHealthcare The Department of Justice has given the green light to insurance giant Cigna Corp.’s planned $67 billion acquisition of pharmacy benefit manager Express Scripts. The move terminates the applicable waiting period under the...
